Our diverse portfolio includes ventures with innovative and disruptive solutions that fundamentally drive transformation and deliver value across the industry.
I am a technology guy and a first time CEO. Triventures helped me fill in the blanks, think through ideas and see the big picture.
We couldn’t have turned to a better VC. Their interventional cardiology know-how and industry relationships are off the charts.
It was great to have Triventures as our lead investor. They helped us put together a syndication in which each partner added unique value.
It is comforting to know that I can call on them at any time of the day on any issue. There is a new challenge every day and they are like the seasoned specialist who is always on call, ready to give a helping hand.
The key added value you want from your investors is for them to become a true partner. You want them to work with you at your side, and together make your company a success. Not many VCs do that… Triventures certainly does.
Triventures believed in us when we were just an idea. Now we have the first image-guided robotic positioning system in the world helping laparoscopic surgeons deliver better care.
Triventures offers more than just financial support. I truly believe we wouldn’t have achieved what we did without their advice and relationships. Orthospace exited to Stryker in March 2019 for $220M.
Any medtech venture would be wise to partner with them. They can help you at every stage in the life of a healthcare start up, from crafting IP all the way to executing a sound bizdev strategy.
6over6 is developing a suite of smartphone optometry tools. With its application, anyone anywhere can obtain a complete prescription, pupillary distance (PD), and astigmatism from any smartphone.
Apica and its spinout ApK developed a suite of implant devices designed to improve transapical surgical access and left ventricular assist device implantation. The companies were acquired by Thoratec in July 2014.
Delivering wearable, neuromodulation therapies that transform the standard of care for chronic disease.
Eyeyon has developed a therapeutic contact lens platform for chronic corneal edema and other corneal-related disorders and post-operative procedures. Eyeyon is also developing a synthetic fluid barrier that has the potential to displace a difficult cadaver based corneal endothelial transplantation procedure, with a simple, easy to implant off the shelf synthetic product.
Vi is developing ‘Hearable’ headsets with embedded sensors to assess physiological parameters in real-time and artificial intelligence algorithms that learn user preferences and act as a virtual trainer.
V-Wave is developing a minimally invasive device for heart failure. The device regulates left atrial pressure (LAP) by shunting excess blood volume away from the left ventricle – the heart’s main pumping chamber.